Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (NAKA) reported equity transactions by director and Chief Investment Officer Evans Tyler Matthew. He received a grant of 250,000 stock options with a $7.06 exercise price, bringing his option holdings to 885,544. He was also granted 56,657 RSUs with a two-year vesting schedule.
In connection with merger agreements, 230 common shares were forfeited and cancelled for no consideration and 3 common shares were issued. All reported share amounts reflect a 1-for-40 reverse stock split of Nakamoto Inc. common stock.
Nakamoto Inc. (symbol: NAKA) is the issuer of record for a Form 4 filing submitted to the SEC.
Nakamoto Inc. (NAKA) reported insider equity activity by Chief Executive Officer and director Bailey David F, who is also a ten percent owner. On August 21, 2026, he received a grant of 62,500 stock options with an exercise price of $7.06 per share, expiring on August 21, 2036. According to the vesting schedule, this non-qualified option vests over four years from August 14, 2025, with a 12‑month cliff; 15,625 shares were vested and became exercisable on the grant date. He also received 70,821 RSUs that time‑vest over two years from August 14, 2026, with no vesting in the first 12 months, then 25% at the cliff and the remaining 75% in equal quarterly installments over the next year. In connection with merger agreements, 3,744 shares of common stock were forfeited and cancelled for no consideration, while 3 shares were issued to him. Additionally, 32,133.836 shares of common stock are reported as held indirectly by his spouse.